We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lam Research vs. Microchip: Which Chip Stock Is the Better Buy?
Read MoreHide Full Article
Key Takeaways
Lam Research appears the better buy, with stronger AI exposure, earnings momentum and near-term visibility.
LRCX sees AI driving NAND, DRAM, HBM, logic and packaging, with 2026 packaging revenue growth above 70%.
Substrate shortages and foundry constraints are lengthening lead times and slowing MCHP's order fulfillment.
Lam Research Corporation (LRCX - Free Report) and Microchip Technology Incorporated (MCHP - Free Report) both provide exposure to the semiconductor industry, but from very different angles. LRCX sells wafer-fabrication equipment used to manufacture increasingly complex chips, while MCHP supplies microcontrollers, analog and other embedded semiconductor products across diverse end markets.
Both companies are benefiting from improving demand and AI-related opportunities. However, differences in growth visibility, earnings momentum, balance sheet strength, valuation and market risks make this an interesting faceoff for investors looking for the better chip stock today.
Let’s find out which of the two is a better investment bet right now.
The Case for Lam Research Stock
Rising semiconductor equipment demand is translating into strong financial growth for LRCX. In the fourth quarter of fiscal 2026, its revenues rose 30% year over year and 15% sequentially to $6.72 billion. Non-GAAP earnings per share (EPS) jumped nearly 37% year over year and 24% sequentially to $1.82. Non-GAAP gross margin expanded 210 basis points sequentially to 52%, while non-GAAP operating margin improved 340 bps to 38.4%. Pricing actions, operational and scale efficiencies, favorable product mix and efficient cost management drove margin improvement.
Lam Research Corporation Price, Consensus and EPS Surprise
AI remains the biggest long-term catalyst. Lam Research now expects calendar year 2026 wafer-fabrication equipment spending in the low-$150 billion range and sees a strong setup for further growth in 2027. AI is driving investment in NAND, DRAM, high-bandwidth memory (HBM), gate-all-around transistors and advanced packaging. LRCX is well positioned because these technologies require more complex etch and deposition processes.
Memory is becoming an especially important growth engine for Lam Research. The company’s NAND revenues more than doubled sequentially in the fourth quarter as customers upgraded production toward 256-layer and higher devices. LRCX expects its served market per NAND wafer to double as customers move from 128-layer technology toward 500-plus-layer architectures.
Its Akara etch platform is also gaining adoption in advanced logic and DRAM. Advanced packaging provides another opportunity as AI chips increasingly rely on chiplets, HBM and larger package designs. The company expects advanced-packaging revenues to grow more than 70% year over year in 2026.
Lam Research's customer support business adds stability to the growth story. Customer support-related revenues reached nearly $2.47 billion in the fourth quarter, rising 43% year over year, supported by upgrades, services and Reliant products. The company is also expanding equipment-intelligence and automation offerings across its installed base.
Lam Research has a strong balance sheet. At the end of fiscal 2026, it had cash, cash equivalents and restricted cash balances of $5.58 billion and long-term debt of $3.73 billion. A strong balance sheet and robust cash flow generation capability have enabled it to enhance shareholders’ wealth through share repurchases and dividend payments. In fiscal 2026, the company generated operating cash flow of $5.86 billion and returned $5.12 billion to shareholders.
The Case for Microchip Stock
Microchip is also delivering robust financial performance. In the first quarter of fiscal 2027, revenues soared 38% year over year to $1.49 billion, while non-GAAP EPS jumped more than 181% to 76 cents. Non-GAAP gross margin improved to 63.8% from 54.3% in the year-ago quarter, while non-GAAP operating margin expanded to 35.1% from 20.7%. Higher factory utilization, lower underutilization charges and improving demand helped profitability rebound quickly as the inventory correction eased.
Microchip Technology Incorporated Price, Consensus and EPS Surprise
The data center end market is emerging as Microchip’s strongest growth opportunity. The company forecasts total data-center revenues will reach about $1 billion in calendar year 2026, up roughly 69% from $591 million in 2025. In the first quarter of fiscal 2027, data center sales surged 97.8% year over year. MCHP expects momentum to extend further in 2027 as new design wins on PCIe Gen6 switches and retimers, storage and NVMe controllers, power-management products, microcontrollers, security chips, timing products and memory products would proceed to production next year.
Microchip also benefits from broad exposure to industrial, aerospace and defense, automotive and communications markets. In the first quarter, these markets grew 24.3%, 45.6%, 29.3% and 53.3%, respectively, from the prior-year period.
Demand indicators have improved. In the first quarter, Microchip registered its strongest bookings in about four years, with book-to-bill finishing well above 1. Distribution sell-through grew 17% sequentially. The company expects second-quarter revenues of $1.589-$1.618 billion, representing 7%-9% sequential growth.
Nonetheless, the company is facing substrate shortages, foundry constraints and pressure on outsourced assembly and test capacity, which are leading to longer lead times and limiting its capability to fulfill orders quickly. Microchip’s highly leveraged balance sheet remains a major concern. Cash and short-term investments were $272.3 million as of June 30, 2026 compared with long-term debt of $5.36 billion. Though the company’s $170 million net debt reduction during the first quarter helped it reduce the net debt-to-adjusted trailing EBITDA ratio, it remained well elevated. Net debt to adjusted trailing EBITDA fell to 2.85X as of June 30 from 3.54X as of March 31.
Though the company has been generating decent cash flows, a highly leveraged balance sheet may limit its capital allocation flexibility. In the trailing 12 months, Microchip has generated operating cash flow of approximately $1.2 billion and returned $985 million to shareholders through dividend payments. MCHP’s trailing 12-month cash flow and shareholders’ returns are significantly lower than LRCX’s.
LRCX vs. MCHP: Growth Outlook
The Zacks Consensus Estimate for Lam Research’s fiscal 2027 and 2028 revenues indicates year-over-year growth of 48.4% and 17.3%, respectively. The consensus mark for earnings calls for increases of 60.4% and 21.7%, respectively.
Microchip’s revenues are projected to increase 35.9% in fiscal 2027 and 16.9% in fiscal 2028. The Zacks Consensus Estimate for earnings calls for a rise of 121.3% for fiscal 2027 and 22.9% for fiscal 2028.
Looking at the two companies’ estimates, Lam Research outperforms on sales growth expectations, while Microchip has stronger earnings growth projections. Nonetheless, earnings estimate revision trends for the last 60 days indicate that analysts are turning more bullish toward LRCX’s long-term bottom-line growth potential.
LRCX Magnitude Consensus Estimate Trend (60 Days)
Image Source: Zacks Investment Research
MCHP Magnitude Consensus Estimate Trend (60 Days)
Image Source: Zacks Investment Research
LRCX vs. MCHP: Valuation and Share Price Performance
Microchip wins the valuation comparison. MCHP trades at a forward P/E multiple of 18.50, considerably below Lam Research's 32.66.
LRCX's higher multiple comes alongside much stronger stock momentum. LRCX shares have surged 83.9% year-to-date compared with MCHP's 15.6% gain. Lam Research's premium valuation reflects its greater exposure to AI-driven wafer-fab spending, stronger near-term revenue momentum and leadership in critical manufacturing technologies.
Final Verdict: Lam Research Is the Better Buy
Microchip offers a cheaper valuation, improving margins and promising data center growth. Substrate shortages and foundry constraints are lengthening lead times and slowing MCHP’s order fulfillment, which could hurt the company’s near-term growth prospects.
On the contrary, Lam Research has the stronger combination of earnings momentum, AI exposure, technology leadership, recurring service revenues and near-term visibility. Its valuation is richer, but rapid growth in NAND, advanced logic, DRAM and packaging offers stronger support for continued earnings expansion. For investors choosing between LRCX and MCHP today, Lam Research appears to be the better investment bet.
View the Zacks #1 Rank List
Image: Bigstock
Lam Research vs. Microchip: Which Chip Stock Is the Better Buy?
Key Takeaways
Lam Research Corporation (LRCX - Free Report) and Microchip Technology Incorporated (MCHP - Free Report) both provide exposure to the semiconductor industry, but from very different angles. LRCX sells wafer-fabrication equipment used to manufacture increasingly complex chips, while MCHP supplies microcontrollers, analog and other embedded semiconductor products across diverse end markets.
Both companies are benefiting from improving demand and AI-related opportunities. However, differences in growth visibility, earnings momentum, balance sheet strength, valuation and market risks make this an interesting faceoff for investors looking for the better chip stock today.
Let’s find out which of the two is a better investment bet right now.
The Case for Lam Research Stock
Rising semiconductor equipment demand is translating into strong financial growth for LRCX. In the fourth quarter of fiscal 2026, its revenues rose 30% year over year and 15% sequentially to $6.72 billion. Non-GAAP earnings per share (EPS) jumped nearly 37% year over year and 24% sequentially to $1.82. Non-GAAP gross margin expanded 210 basis points sequentially to 52%, while non-GAAP operating margin improved 340 bps to 38.4%. Pricing actions, operational and scale efficiencies, favorable product mix and efficient cost management drove margin improvement.
Lam Research Corporation Price, Consensus and EPS Surprise
Lam Research Corporation price-consensus-eps-surprise-chart | Lam Research Corporation Quote
AI remains the biggest long-term catalyst. Lam Research now expects calendar year 2026 wafer-fabrication equipment spending in the low-$150 billion range and sees a strong setup for further growth in 2027. AI is driving investment in NAND, DRAM, high-bandwidth memory (HBM), gate-all-around transistors and advanced packaging. LRCX is well positioned because these technologies require more complex etch and deposition processes.
Memory is becoming an especially important growth engine for Lam Research. The company’s NAND revenues more than doubled sequentially in the fourth quarter as customers upgraded production toward 256-layer and higher devices. LRCX expects its served market per NAND wafer to double as customers move from 128-layer technology toward 500-plus-layer architectures.
Its Akara etch platform is also gaining adoption in advanced logic and DRAM. Advanced packaging provides another opportunity as AI chips increasingly rely on chiplets, HBM and larger package designs. The company expects advanced-packaging revenues to grow more than 70% year over year in 2026.
Lam Research's customer support business adds stability to the growth story. Customer support-related revenues reached nearly $2.47 billion in the fourth quarter, rising 43% year over year, supported by upgrades, services and Reliant products. The company is also expanding equipment-intelligence and automation offerings across its installed base.
Lam Research has a strong balance sheet. At the end of fiscal 2026, it had cash, cash equivalents and restricted cash balances of $5.58 billion and long-term debt of $3.73 billion. A strong balance sheet and robust cash flow generation capability have enabled it to enhance shareholders’ wealth through share repurchases and dividend payments. In fiscal 2026, the company generated operating cash flow of $5.86 billion and returned $5.12 billion to shareholders.
The Case for Microchip Stock
Microchip is also delivering robust financial performance. In the first quarter of fiscal 2027, revenues soared 38% year over year to $1.49 billion, while non-GAAP EPS jumped more than 181% to 76 cents. Non-GAAP gross margin improved to 63.8% from 54.3% in the year-ago quarter, while non-GAAP operating margin expanded to 35.1% from 20.7%. Higher factory utilization, lower underutilization charges and improving demand helped profitability rebound quickly as the inventory correction eased.
Microchip Technology Incorporated Price, Consensus and EPS Surprise
Microchip Technology Incorporated price-consensus-eps-surprise-chart | Microchip Technology Incorporated Quote
The data center end market is emerging as Microchip’s strongest growth opportunity. The company forecasts total data-center revenues will reach about $1 billion in calendar year 2026, up roughly 69% from $591 million in 2025. In the first quarter of fiscal 2027, data center sales surged 97.8% year over year. MCHP expects momentum to extend further in 2027 as new design wins on PCIe Gen6 switches and retimers, storage and NVMe controllers, power-management products, microcontrollers, security chips, timing products and memory products would proceed to production next year.
Microchip also benefits from broad exposure to industrial, aerospace and defense, automotive and communications markets. In the first quarter, these markets grew 24.3%, 45.6%, 29.3% and 53.3%, respectively, from the prior-year period.
Demand indicators have improved. In the first quarter, Microchip registered its strongest bookings in about four years, with book-to-bill finishing well above 1. Distribution sell-through grew 17% sequentially. The company expects second-quarter revenues of $1.589-$1.618 billion, representing 7%-9% sequential growth.
Nonetheless, the company is facing substrate shortages, foundry constraints and pressure on outsourced assembly and test capacity, which are leading to longer lead times and limiting its capability to fulfill orders quickly. Microchip’s highly leveraged balance sheet remains a major concern. Cash and short-term investments were $272.3 million as of June 30, 2026 compared with long-term debt of $5.36 billion. Though the company’s $170 million net debt reduction during the first quarter helped it reduce the net debt-to-adjusted trailing EBITDA ratio, it remained well elevated. Net debt to adjusted trailing EBITDA fell to 2.85X as of June 30 from 3.54X as of March 31.
Though the company has been generating decent cash flows, a highly leveraged balance sheet may limit its capital allocation flexibility. In the trailing 12 months, Microchip has generated operating cash flow of approximately $1.2 billion and returned $985 million to shareholders through dividend payments. MCHP’s trailing 12-month cash flow and shareholders’ returns are significantly lower than LRCX’s.
LRCX vs. MCHP: Growth Outlook
The Zacks Consensus Estimate for Lam Research’s fiscal 2027 and 2028 revenues indicates year-over-year growth of 48.4% and 17.3%, respectively. The consensus mark for earnings calls for increases of 60.4% and 21.7%, respectively.
Microchip’s revenues are projected to increase 35.9% in fiscal 2027 and 16.9% in fiscal 2028. The Zacks Consensus Estimate for earnings calls for a rise of 121.3% for fiscal 2027 and 22.9% for fiscal 2028.
Looking at the two companies’ estimates, Lam Research outperforms on sales growth expectations, while Microchip has stronger earnings growth projections. Nonetheless, earnings estimate revision trends for the last 60 days indicate that analysts are turning more bullish toward LRCX’s long-term bottom-line growth potential.
LRCX Magnitude Consensus Estimate Trend (60 Days)
Image Source: Zacks Investment Research
MCHP Magnitude Consensus Estimate Trend (60 Days)
Image Source: Zacks Investment Research
LRCX vs. MCHP: Valuation and Share Price Performance
Microchip wins the valuation comparison. MCHP trades at a forward P/E multiple of 18.50, considerably below Lam Research's 32.66.
LRCX's higher multiple comes alongside much stronger stock momentum. LRCX shares have surged 83.9% year-to-date compared with MCHP's 15.6% gain. Lam Research's premium valuation reflects its greater exposure to AI-driven wafer-fab spending, stronger near-term revenue momentum and leadership in critical manufacturing technologies.
Final Verdict: Lam Research Is the Better Buy
Microchip offers a cheaper valuation, improving margins and promising data center growth. Substrate shortages and foundry constraints are lengthening lead times and slowing MCHP’s order fulfillment, which could hurt the company’s near-term growth prospects.
On the contrary, Lam Research has the stronger combination of earnings momentum, AI exposure, technology leadership, recurring service revenues and near-term visibility. Its valuation is richer, but rapid growth in NAND, advanced logic, DRAM and packaging offers stronger support for continued earnings expansion. For investors choosing between LRCX and MCHP today, Lam Research appears to be the better investment bet.
Currently, Lam Research carries a Zacks Rank #2 (Buy), making the stock a must-pick compared with Microchip, which has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.